This drug may cause drowsiness, if affected, do not drive or operate machinery.
Symptoms: Convulsions, hallucinations, agitation, coma, tachycardia w/ a hyperdynamic circulation. Management: Supportive treatment. May perform gastric lavage, forced emesis or diuresis. Administer activated charcoal, to prevent absorption. May give diazepam for convulsions, hallucinations, and β-adrenergic blockers for CV complications.
Increased risk of convulsion w/ TCA. Additive adverse effect w/ other antimuscarinic or sympathomimetic agents. Potentially Fatal: May cause hypertensive crisis w/ MAOI(s).
False positive result to screening test for benzodiazepines and opioids.
Description: Nefopam is a potent, centrally-acting, non-opioid analgesic w/ rapid onset of action. It acts on the CNS, but the exact mechanism of action is still unclear. It also has antimuscarinic and sympathomimetic actions. Pharmacokinetics: Absorption: Absorbed from the GI tract. Time to peak plasma concentration: Approx 1-3 hr. Distribution: Enters breast milk. Plasma protein binding: Approx 73%. Metabolism: Extensively metabolised in the liver. Excretion: Mainly via urine (<5% as unchanged drug); faeces (8%). Elimination half-life: Approx 4 hr.